Literature DB >> 11291553

Gene expression of insulin-like growth factors and receptors in neoplastic prostate tissues: correlation with clinico-pathological parameters.

J A Figueroa1, S De Raad, V O Speights, J J Rinehart.   

Abstract

The insulin-like growth factor (IGF) system has been shown to regulate prostate cancer cell growth in vitro and, possibly, in vivo. In this study we examined RNA expression of IGF ligands and their receptors in 23 paired benign and neoplastic prostate tissues. In addition to comparing gene expression of IGF ligands and receptors between benign and neoplastic tissue samples, we correlated IGF-I, IGF-II, IGFR-1, and IGFR-2 RNA levels in tumor samples with prognostic clinico-pathological parameters such as stage, grade, Gleason score, perineural or extraprostatic invasion. We found higher IGF-I RNA levels in benign vs. malignant tissues (p = 0.014), whereas IGF-II RNA expression was higher in tumors with high Gleason score (GS) (p = 0.045). Using the Spearman rank correlation test we also found a positive correlation between IGFR-2 RNA levels and GS (p = 0.01). No correlation was found between expression of IGF ligands and receptors and tumor grade, stage perineural invasion, or extraprostatic involvement. We conclude that differential expression of certain IGF system components may be important in the biology and clinical behavior of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11291553     DOI: 10.1081/cnv-100000072

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  8 in total

Review 1.  Tumor control versus adverse events with targeted anticancer therapies.

Authors:  Dorothy M K Keefe; Emma H Bateman
Journal:  Nat Rev Clin Oncol       Date:  2011-12-20       Impact factor: 66.675

2.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

3.  PDLIM4, an actin binding protein, suppresses prostate cancer cell growth.

Authors:  Donkena Krishna Vanaja; Michael E Grossmann; John C Cheville; Mozammel H Gazi; Aiyu Gong; Jin San Zhang; Katalin Ajtai; Thomas P Burghardt; Charles Y F Young
Journal:  Cancer Invest       Date:  2009-03       Impact factor: 2.176

Review 4.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

5.  Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.

Authors:  Caterina Mancarella; Irene Casanova-Salas; Ana Calatrava; Maria García-Flores; Cecilia Garofalo; Andrea Grilli; José Rubio-Briones; Katia Scotlandi; José Antonio López-Guerrero
Journal:  BMC Cancer       Date:  2017-05-25       Impact factor: 4.430

6.  Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation.

Authors:  Akane Yamagishi; Yuki Ikeda; Masayoshi Ikeuchi; Ryuzaburo Yuki; Youhei Saito; Yuji Nakayama
Journal:  Int J Mol Sci       Date:  2020-02-05       Impact factor: 5.923

Review 7.  Trends in Gene Expression Profiling for Prostate Cancer Risk Assessment: A Systematic Review.

Authors:  Zhaoyi Chen; Travis Gerke; Victoria Bird; Mattia Prosperi
Journal:  Biomed Hub       Date:  2017-05-17

8.  Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes.

Authors:  Won Kyung Kim; Adam W Olson; Jiaqi Mi; Jinhui Wang; Dong-Hoon Lee; Vien Le; Alex Hiroto; Joseph Aldahl; Christian H Nenninger; Alyssa J Buckley; Robert Cardiff; Sungyong You; Zijie Sun
Journal:  Nat Commun       Date:  2022-07-28       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.